ArticleSubstance use & misuse2020
Communication Experiences of DATA-Waivered Physicians with Community Pharmacists: A Qualitative Study.
Article in Substance use & misuse, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Pilot evaluation of a pharmacist-led technical assistance program to address buprenorphine dispensing in community pharmacies.Exploratory research in clinical and social pharmacy · 2026Article
- Pharmacists' Knowledge and Perceptions of Buprenorphine at New York State Pharmacies: Identifying the Extent of Pharmacy-Level Barriers to Access Buprenorphine.Clinical therapeutics · 2025Article
- Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel.Drug and alcohol dependence reports · 2025Article
- Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies.Drug and alcohol dependence reports · 2024Article
- Factors in rural community buprenorphine dispensing.Exploratory research in clinical and social pharmacy · 2023Article
- Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey.Addiction science & clinical practice · 2022Article
- 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.The International journal on drug policy · 2022Article
- Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.Substance abuse · 2022Article
- Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.The International journal on drug policy · 2021Article
- U.S. student pharmacist perceptions of the pharmacist's role in methadone for opioid use disorder: A qualitative study.SAGE open medicine · 2021Article
- Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.The International journal on drug policy · 2020Article
- Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.Substance abuse · 2020Article
- Demographic and socioeconomic correlates to buprenorphine access in pharmacies.Journal of the American Pharmacists Association : JAPhAArticle
- Mapping Buprenorphine Access at Philadelphia Pharmacies.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.